MedTech Dive January 18, 2024
A study found the sensitivity of the device was 96%, compared with 83% for primary care physicians.
Dive Brief:
- Dermasensor has received 510(k) clearance for a wireless, handheld device designed to detect common skin cancers.
- The device uses artificial intelligence (AI) to analyze light scattered back from skin lesions. Cancerous and benign lesions reportedly give off different light signatures because of cellular and subcellular changes in tumors, according to Dermasensor, and the AI is trained to detect those distinct patterns.
- Dermasensor received Food and Drug Administration clearance after a Mayo Clinic-led clinical trial found the overall sensitivity of the device for malignancy detection was 96%, compared to 83% for primary care physicians.
Dive Insight:
Most skin cancers...
Today's Sponsors
Today's Sponsor